Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2021

01-01-2021 | Rosuvastatin | Original Article

Efficacy of oral rosuvastatin intervention on HDL and its associated proteins in men with type 2 diabetes mellitus

Authors: Sriram Naresh, Aparna R. Bitla, P. V. L. N. Srinivasa Rao, Alok Sachan, Yadagiri Lakshmi Amancharla

Published in: Endocrine | Issue 1/2021

Login to get access

Abstract

Purpose

High-density lipoprotein (HDL) undergoes structural and functional modification in patients with type 2 diabetes mellitus (T2DM). There are limited data on effect of rosuvastatin on HDL-associated proteins and the antiatherogenic effects of rosuvastatin. The present study intended to study the efficacy of rosuvastatin intervention on HDL-associated proteins and its other antiatherogenic effects in men with T2DM.

Methods

Men with T2DM on oral antidiabetic treatment, with LDL-C levels > 75 mg/dL and willing for rosuvastatin intervention (20 mg/day orally for a period of 12 weeks), were included. Fasting glucose, lipid profile were measured using standard methods. Oxidized low-density lipoprotein (oxLDL), oxidized HDL (oxHDL), paraoxonase-1 (PON-1), tumour necrosis factor-α (TNF-α) and lecithin:cholesterol acyltransferase (LCAT) in serum were measured by ELISA; serum myeloperoxidase (MPO) by spectrophotometric method and cholesterol efflux by fluorometric assay. Carotid intima-media thickness (cIMT) measurement to assess vascular health status was done using doppler.

Results

Rosuvastatin produced a significant decrease (p < 0.05) in lipids (total cholesterol, triglycerides, LDL-C); oxidative stress (oxLDL, oxHDL, MPO); inflammation (TNF-α); LCAT concentration; cIMT; significant increase in antiatherogenic HDL and cholesterol efflux (p < 0.05) and no change in apoA-I levels from baseline to 12 weeks of follow-up. A decrease in MPO activity was found to be independently associated with an increase in cholesterol efflux.

Conclusions

Post intervention there is a quantitative and qualitative improvement in HDL, which helps in its reverse cholesterol transport (RCT) and antioxidant functions. Improvement in HDL functions and suppression of inflammation by rosuvastatin lead to regression in cIMT, which is beneficial in decreasing the progression of cardiovascular disease (CVD) in men with diabetes.
Literature
1.
N.J. Stone, J.G. Robinson, A.H. Lichtenstein et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 63(25 Pt B), 2889–2934 (2014)PubMed
2.
H. Soran, R. Dent, P. Durrington, Evidence-based goals in LDL-C reduction. Clin. Res. Cardiol. 106(4), 237–248 (2017)PubMedPubMedCentral
3.
West of Scotland Coronary Prevention Study Group, Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97(15), 1440–1445 (1998)
4.
F.M. Sacks, L.A. Moyé, B.R. Davis et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation 97(15), 1446–1452 (1998)PubMed
5.
S. Lund-katz, M.C. Phillips, High density lipoprotein structure-function and role in reverse cholesterol transport. Subcell. Biochem. 51, 183–227 (2010)PubMedPubMedCentral
6.
S. Zhong, D.S. Sharp, J.S. Grove et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Investig. 97(12), 2917–2923 (1996)PubMedPubMedCentral
7.
8.
E.S. Istvan, J. Deisenhofer, Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292(5519), 1160–1164 (2001)PubMed
9.
J.E. Feliciano-Alfonso, Rosuvastatin: role in cardiovascular high-risk patient. Rev. Fac. Med. 61(1), 41–51 (2013)
10.
D. Sviridov, A. Hoang, E. Ooi et al. Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. Atherosclerosis 197(2), 732–739 (2008)PubMed
11.
P.R.J. Ames, A. Ortiz-Cadenas, I. Garcia De La Torre, A et al. Rosuvastatin treatment is associated with a decrease of serum oxidised low-density lipoprotein/beta2-glycoprotein I complex concentration in type 2 diabetes. Br. J. Diabetes Vasc. Dis. 10(6), 292–299 (2010)
12.
H. Takagi, T. Umemoto; ALICE group, A meta-analysis of randomised head-to-head trials for effects of rosuvastatin versus atorvastatin on apolipoproteins profiles. Am. J. Cardiol. 113(2), 292–301 (2014)PubMed
13.
B. Verges, E. Florentin, S. Baillot-Rudoni et al. Rosuvastatin 20 mg restores normal HDL-apo A-I kinetics in type 2 diabetes. J. Lipid Res. 50(6), 1209–1215 (2009)PubMedPubMedCentral
14.
R.H. Knopp, X. Zhu, Multiple beneficial effects of estrogen on lipoprotein metabolism. J. Clin. Endocrinol. Metab. 82(12), 3952–3964 (1997)PubMed
15.
K. Griffiths, A. Pazderska, M. Ahmed et al. Type 2 diabetes in young females results in increased serum amyloid a and changes to features of high density lipoproteins in both HDL2 and HDL3. J. Diabetes Res. 2017, 1314864 (2017)PubMedPubMedCentral
16.
G.A. Woodard, M.M. Brooks, E. Barinas-Mitchell et al. Lipids, menopause, and early atherosclerosis in Study of Women’s Health Across the Nation Heart Women. Menopause 18(4), 376–384 (2011)PubMedPubMedCentral
17.
American Diabetes Association. Classification and diagnosis of diabetes Sec. 2. In Standards of medical care in diabetes—2016. Diabetes Care. 39(Suppl. 1), S13–S22 (2016)
18.
A.M. Rao, R. Apoorva, U. Anand, C.V. Anand, G. Venu, Effect of hemodialysis on plasma myeloperoxidase activity in end stage renal disease patients. Indian J. Clin. Biochem. 27(3), 253–258 (2012)PubMedPubMedCentral
19.
D.J. Gordon, J.L. Probstfield, R.J. Garrison et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79(1), 8–15 (1989)PubMed
20.
A.V. Khera, M. Cuchel, M. de la Llera-Moya et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364(2), 127–135 (2011)PubMedPubMedCentral
21.
D.W. Bilheimer, S.M. Grundy, M.S. Brown, J.L. Goldstein, Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc. Natl. Acad. Sci. USA 80(13), 4124–4128 (1983)PubMedPubMedCentral
22.
K.Y. Jung, K.M. Kim, S.K. Han et al. Effect of rosuvastatin on cholesterol efflux capacity and endothelial function in type 2 diabetes mellitus and dyslipidemia. Circ. J. 82(5), 1387–1395 (2018)PubMed
23.
C.P. Shah, D.K. Kumbla, A. Moorthy et al. A post-marketing study evaluating the lipid-altering efficacy and safety of approved dose ranges of rosuvastatin in Indian hyperlipidemia patients in routine clinical practice (ROSUVEES). J. Indian Coll. Cardiol. 5(4), 282–290 (2015)
24.
S.J. Nicholls, G. Brandrup-wognsen, M. Palmer et al. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am. J. Cardiol. 105(1), 69–76 (2010)PubMed
25.
J. Yang, L.J. Li, K. Wang et al. Race differences: modeling the pharmacodynamics of rosuvastatin in Western and Asian hypercholesterolemia patients. Acta Pharmacol. Sin. 32(1), 116–125 (2011)PubMed
26.
M. Triolo, W. Annema, J.F. Deboer et al. Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes. Eur. J. Clin. Investig. 44(3), 240–248 (2014)
27.
M. Miyamoto-Sasaki, T. Yasuda, T. Monguchi et al. Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients. J. Atheroscler. Thromb. 20(9), 708–716 (2013)PubMed
28.
H. Soran, Y. Liu, S. Adam et al. A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial. J. Clin. Lipidol. 12(1), 44–55 (2018)PubMed
29.
N.D. Vaziri, K. Liang, Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome. Am. J. Nephrol. 24(6), 606–613 (2004)PubMed
30.
T. Shimizu, S. Miura, H. Tanigawa et al. Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet. Arterioscler. Thromb. Vasc. Biol. 34(10), 2246–2253 (2014)PubMed
31.
D. Bhatnagar, P.N. Durrington, S. Kumar, M.I. Mackness, J. Dean, A.J. Boulton, Effect of treatment with a hydroxy methyl glutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM. Diabetes 44(4), 460–465 (1995)PubMed
32.
L. Masana, A. Cabré, M. Heras et al. Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients. Atherosclerosis 238(2), 213–219 (2015)PubMed
33.
J.M. Hoeg, S. Santamarina-Fojo, A.M. Berard et al. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc. Natl. Acad. Sci. USA 93(21), 11448–11453 (1996)PubMedPubMedCentral
34.
R.P. Dullaart, F. Perton, W.J. Sluiter, R. de Vries, A. van Tol, Plasma lecithin: cholesterol acyltransferase activity is elevated in metabolic syndrome and is an independent marker of increased carotid artery intima media thickness. J. Clin. Endocrinol. Metab. 93(12), 4860–4866 (2008)PubMed
35.
A.B. Kosek, D. Durbin, A. Jonas, Binding affinity and reactivity of lecithin cholesterol acyltransferase with native lipoproteins. Biochem. Biophys. Res. Commun. 258(3), 548–551 (1999)PubMed
36.
A. Hafiane, J. Genest, High density lipoproteins: measurement techniques and potential biomarkers of cardiovascular risk. BBA Clin. 3, 175–188 (2015)PubMedPubMedCentral
37.
A.A. Abdin, M.A. Hassanien, E.A. Ibrahim, S.A. El-Noeman, Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy. J. Diabetes Complicat. 24(5), 325–333 (2010)
38.
J. Christison, A. Karjalainen, J. Brauman, F. Bygrave, R. Stocker, Rapid reduction and removal of HDL-but not LDL-associated cholesteryl ester hydroperoxides by rat liver perfused in situ. Biochem. J. 314(Pt 3), 739–742 (1996)PubMedPubMedCentral
39.
K. Torimoto, Y. Okada, H. Mori et al. Efficacy of combination of ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes. Lipids Health Dis. 12, 137 (2013)PubMedPubMedCentral
40.
E. Mandosi, M. Fallarino, A. Gatti et al. Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNF alpha levels in type 2 diabetes. J. Atheroscler. Thromb. 17(6), 539–545 (2010)PubMed
41.
L. Wei, M. Yamamoto, M. Harada, M. Otsuki, Treatment with atorvastatin attenuates progression of insulin resistance and pancreatic fibrosis in the Otsuka Long-Evans Tokushima fatty rats. Metab. Clin. Exp. 65(2), 41–53 (2016)PubMed
42.
K. Yanagi, T. Monden, S. Ikeda et al. A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes. Adv. Ther. 28, 160–171 (2011)PubMed
43.
G. Ma, S. Bi, Effect of rosuvastatin on vascular endothelial functions and inflammatory factors of patients with type 2 diabetes mellitus and coronary heart disease. Exp. Ther. Med. 17(1), 332–336 (2019)PubMed
44.
K. Wu, S. Tian, H. Zhou, Y. Wu, Statins protect human endothelial cells from TNF-induced inflammation via ERK5 activation. Biochem. Pharmacol. 85(12), 1753–1760 (2013)PubMed
45.
A. Link, T. Ayadhi, M. Böhm, G. Nickenig, Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur. Heart J. 27(24), 2945–2955 (2006)PubMed
46.
A. Mohan, S. Sada, B.S. Kumar et al. Subclinical atherosclerosis in patients with rheumatoid arthritis by utilizing carotid intima-media thickness as a surrogate marker. Indian J. Med. Res. 140(3), 379–386 (2014)PubMedPubMedCentral
47.
Society of Atherosclerosis Imaging and Prevention developed in collaboration with the International Atherosclerosis Society, Appropriate use criteria for carotid intima media thickness testing. Atherosclerosis 214(1), 43–46 (2011)
48.
P. Greenland, J.S. Alpert, G.A. Beller et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 122(25), e584–e636 (2010)PubMed
49.
A.V. Khera, O.V. Demler, S.J. Adelman et al. Cholesterol efflux capacity, high-density lipoprotein particle number, and incident cardiovascular events: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). Circulation 135(25), 2494–2504 (2017)PubMedPubMedCentral
50.
F.R. Jornayvaz, M.C. Brulhart-meynet, R.W. James, Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients. Nutr. Metab. Cardiovasc. Dis. 19(9), 613–619 (2009)PubMed
51.
P.G. Scheffer, R.K. Schindhelm, V.M. vanVerschuer et al. No effect of atorvastatin and simvastatin on oxidative stress in patients at high risk for cardiovascular disease. Neth. J. Med. 71(7), 359–365 (2013)PubMed
52.
J.R. Crouse, J.S. Raichlen, W.A. Riley, METEOR Study Group et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 297(12), 1344–1353 (2007)PubMed
Metadata
Title
Efficacy of oral rosuvastatin intervention on HDL and its associated proteins in men with type 2 diabetes mellitus
Authors
Sriram Naresh
Aparna R. Bitla
P. V. L. N. Srinivasa Rao
Alok Sachan
Yadagiri Lakshmi Amancharla
Publication date
01-01-2021
Publisher
Springer US
Published in
Endocrine / Issue 1/2021
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02472-5

Other articles of this Issue 1/2021

Endocrine 1/2021 Go to the issue

Original Article

A mutation in NOTCH2 gene first associated with Hajdu–Cheney syndrome in a Greek family: diversity in phenotype and response to treatment

Letter to the Editor

Letter to “High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?”

Original Article

Polymorphisms of the genes CTLA4, PTPN22, CD40, and PPARG and their roles in Graves’ disease: susceptibility and clinical features

Original Article

Clinical features, risk of mass enlargement, and development of endocrine hyperfunction in patients with adrenal incidentalomas: a long-term follow-up study

Original Article

Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study

Original Article

Incidence of primary congenital hypothyroidism and relationship between diagnostic categories and associated malformations
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits